Influenza viruses are among the most likely triggers of future pandemics. A research team from the Helmholtz Center for Infection Research (HZI) and the Medical Center—University of Freiburg has ...

This manuscript characterizes a mutated clone of RNA polymerase I in yeast, referred to as SuperPol, to understand the mechanisms of RNA polymerase I elongation and termination. The authors present ...

At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation there ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

The RTF letter referenced herein does not impact this ... CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

Combined checkpoint inhibition therapy targeting the programmed cell death 1 (PD-L1) and cytotoxic T-lymphocyte ... the patient’s diagnosis and treatment occurred at outside institutions and not at ...

And unlike proteins, they are not genetically encoded, so cells can't be genetically engineered to produce sugars labeled with fluorescent tags such as green fluorescent protein. One of the key ...

BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...

Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft ProductMARIETTA, Ga., May 05 ...